Authors: Nicha Wongjarupong, Mohammed Al-Hameed, Sakolwan Suchartikitwong, BuravejAssavapongpaiboon, Behrouz Salehian.
Objective: Glucagon-like peptide-1 receptors agonists (GLP-1 RAs) are adjunctive treatment for patients with diabetes. The mechanism of action is to increase insulin and decrease glucagon secretion along with delay of gastric emptying which has superior effect toward post-prandial blood glucose level. However, the GLP-1RAs effect on gastric emptying (GE) on patients with compromised gastric motility, especially in diabetes patients, is not well-documented. The aim of this systematic review is to determine the effects of GLP-1 RAs on gastric motility in healthy subjects, diabetic type 1 and type 2 patients and to identify the specific conditions that could alter these effects.
Research design and methods: A search was conducted for studies of patients received GLP-1 RAs with control group and included gastric motility measurement as an outcome. We included studies published up to January, 2017 using PubMed, Scopus, Web of Sciences, and Clinicaltrial.gov databases. The studies were classified by studied subjects and method of GE measurement.
Results: Nineteen studies were included in the review, with 4 studies in healthy, 2 in obese, 5 in diabetes type 1 and 8 in diabetes type 2 subjects. Fifteen studies showed significantly dose-responded decrease of gastric motility and we found this decrease in all three groups of studied patients. Studies that did not demonstrate delay in gastric motility include study with specific condition including relatively low dose of GLP-1 RA, hypoglycemic stage and concomitant high-fat diet.
Conclusions: GLP-1 RAs has potential effect to decrease gastric motility in non-diabetes and diabetes patients.
This effect correlates with its known effect to decrease post-prandial blood glucose level.